#China #Hangzhou #Innovent Biologics #Altruist Biologics #PPQ Campaign

Altruist Biologics Completes First Commercial PPQ Campaign

Altruist Biologics, a subsidiary of Innovent Biologics and a leader in contract development and manufacturing organization (CDMO), has reached a remarkable milestone with the successful execution of its first commercial Process Performance Qualification (PPQ) campaign at its state-of-the-art Hangzhou facility. This campaign, which involved the production of three consecutive batches at 20,000 liters each, showcases the organization’s robust capabilities in managing large-scale production.

The achievement signifies not only the technical prowess of Altruist Biologics but also its commitment to operational excellence and product quality. The campaign was designed to optimize efficiency while reducing costs. According to company reports, advanced manufacturing processes enabled a cost reduction of nearly 20%, while also enhancing yield performance to an impressive 80%. This was made possible through a combination of innovative automation strategies, strategic sourcing of raw materials, and ongoing process enhancements.

Dr. Kaisong Zhou, the Chairman and CEO of Altruist Biologics, expressed pride in this achievement, stating, "The successful completion of our first commercial PPQ campaign on the 20,000-liter production line signifies an important milestone for Altruist Biologics. It reflects our commitment to providing reliable manufacturing solutions as our clients transition from late-stage development to commercial supply."

In just two years, Altruist's facility has become a hub of biomanufacturing, housing the first and largest stainless steel bioreactors of this scale in China. The existing four 20,000-liter bioreactors are at the forefront of industry standards, with plans to expand the facility capacity further. An additional four bioreactors are expected to be operational by 2027, which will increase the total production capacity from 80,000 liters to a staggering 172,000 liters.

The commitment to quality and efficiency is evident in Altruist Biologics’ track record. With over a decade of experience in bioprocessing, they have developed numerous drugs while maintaining an impressive success rate exceeding 99.8% across more than 2,000 commercial batches. Their facilities in Suzhou and Hangzhou boast a combined total production capacity of 232,000 liters, cementing their position as a key player in the biopharmaceutical manufacturing sector.

As they strive for further innovation and operational excellence, Altruist Biologics is devoted to supporting their clients in developing high-quality, affordable biopharmaceuticals. This latest accomplishment not only enhances their operational capability but also paves the way towards making a significant impact on patients worldwide.

For more information on Altruist Biologics and their comprehensive service offerings, you can visit www.altruistbio.com.

Key Takeaways:

• - Altruist Biologics successfully completed its first commercial PPQ campaign with three large-scale batches.
• - The campaign's advanced processes led to a nearly 20% reduction in costs and an 80% increase in yield.
• - Plans are in place to increase production capacity with more bioreactors to meet future demands in biopharmaceuticals.